Results 141 to 150 of about 21,749 (244)

MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies. [PDF]

Front Med (Lausanne)
Wang Y, Liu C, Hu Y, Sun X, Zhang W, Zhu W.   +5 more
europepmc   +1 more source

The Sleeping Giant: Metabolism and Autophagy in the Generation and Survival of Dormant Polyploid Giant Cancer Cells

MedComm, Volume 7, Issue 10, October 2026.
Polyploid giant cancer cells (PGCCs) arise in response to stress and play a critical role in therapy resistance and tumor dormancy. These cells can evade conventional treatments and later contribute to cancer relapse by generating progeny through nonmitotic, amitotic mechanisms.
Silvia Guil‐Luna, María Teresa Sánchez‐Montero, Alejandra Díaz‐Chacón, Antonio Rodríguez‐Ariza   +3 more
wiley   +1 more source

The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production. [PDF]

Stem Cells Transl Med
Wang X, Xia M, Cai Y, Huo Z, Zhong Y, Su P, Liu C, Wang H, Shen X, Wang F, Xu J, Zhou J.   +11 more
europepmc   +1 more source

Extracellular Vesicles: Classification, Biological Functions, Diseases, and Therapeutic Opportunities

MedComm, Volume 7, Issue 10, October 2026.
• EV content maintains cellular homeostasis and is involved in several disease onset and progression. • miRNA export in EVs depends on: RNA‐binding proteins recognizing motif sequences and on epitranscriptomic modifications. • The disclosure of delivery mechanisms is crucial for developing personalized EV‐based therapeutic tools. ABSTRACT Extracellular
Sabrina Garbo, Francesco Marocco, Clemens Zwergel, Marco Tripodi, Cecilia Battistelli   +4 more
wiley   +1 more source

Acute Megakaryocytic Leukemia [PDF]

Mayo Clinic Proceedings, 1989
openaire   +2 more sources

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Radiotherapy‐Induced Side Effects: Epidemiology, Pathogenesis, Prevention and Treatments

MedComm, Volume 7, Issue 10, October 2026.
Radiotherapy for malignancies frequently injures the organs’ systems through oxidative stress, fibrosis, inflammation, and vascular damage. This review systematically maps the epidemiology, pathogenesis, and emerging therapies to propose a mechanism‑network‑targeted framework for integrated, personalized care in radiation oncology.
Xiaowen Ma, Xiaoxuan Zhang, Pujun Zhao, Jiaxin Yang, Zhihao Li, Xiaoyang Han, Yixuan Wang, Zhenzhen Cui, Nian Liu, Min Li   +9 more
wiley   +1 more source

Stag2-dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.

Blood
Sudunagunta VS, Stewart EM, Chen Y, Yan H, Fernando S, Scoca V, Pantazi J, Deng R, Xu JJ, Mohandas N, Viny AD.   +10 more
europepmc   +1 more source

Expanding the Treatment Window for the FDA-Approved Radiation Countermeasure Nplate. [PDF]

Mil Med
Holmes-Hampton GP, Dronamraju VR, Kumar VP, Managbanag JR, Whiteway SL, Ghosh SP.   +5 more
europepmc   +1 more source